Skip to content
The People's CodeSearch
Menu

Changes to the Code

H.R. 8630 · PEAT Act of 2026 ·

In committee · step 2 of 5

Sections are cited like “7 U.S.C. § 2012”: 7 of the , 2012.

42 U.S.C. § 262 Regulation of biological products

+4 −12 of 3 shown
More for 42 U.S.C. § 262
Read § 262Only this section
3 changes the bill asks for here, 2 carried out
  1. Carried out:

    by striking The term and inserting the following:(A) The term; and

  2. Carried out:

    by adding at the end the following:(B) A biologic described in subparagraph (A) may not be treated as a biological product based solely on the presence of a protein that is a clinically inactive component in such biologic..

  3. Not carried out:

    Section 351(i)(1) of the Public Health Service Act (42 U.S.C. 262(i)(1)) is amended in subparagraph (A), as designated by subsection (a)(1), by striking protein , and inserting protein,.

    “protein ,” isn't in § 262(i)(1)(A) in the Code as we have it. The law may have changed since the bill was drafted.

    Technical detail“protein ,” not found in /us/usc/t42/s262/i/1/A

§ 262(i)“Biological product” defined(1)–(2)

Start of § 262 to (h) unchanged

WhereMarkThe Code nowMarkAs the bill would leave it
(i)(i) “Biological product” defined(i) “Biological product” defined
In this section:In this section:
(1)(1) (1)
(1)(A)(A) [inserted: ]
[inserted: The term “biological product” means a virus, therapeutic serum, toxin, antitoxin, vaccine, blood, blood component or derivative, allergenic product, protein, or analogous product, or arsphenamine or derivative of arsphenamine (or any other trivalent organic arsenic compound), applicable to the prevention, treatment, or cure of a disease or condition of human beings.]
(1)(B)(B) [inserted: ]
[inserted: A biologic described in subparagraph (A) may not be treated as a biological product based solely on the presence of a protein that is a clinically inactive component in such biologic.]
(1)[struck: The term “biological product” means a virus, therapeutic serum, toxin, antitoxin, vaccine, blood, blood component or derivative, allergenic product, protein, or analogous product, or arsphenamine or derivative of arsphenamine (or any other trivalent organic arsenic compound), applicable to the prevention, treatment, or cure of a disease or condition of human beings.]
(2)(2) (2)
The term “biosimilar” or “biosimilarity”, in reference to a biological product that is the subject of an application under subsection (k), means—The term “biosimilar” or “biosimilarity”, in reference to a biological product that is the subject of an application under subsection (k), means—
(2)(A)(A) (A)
that the biological product is highly similar to the reference product notwithstanding minor differences in clinically inactive components; andthat the biological product is highly similar to the reference product notwithstanding minor differences in clinically inactive components; and

Rest of § 262 unchanged

Step through the changes